Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
Clinical trial NCT01721772 · COMPLETED
Trial details
- NCT number
- NCT01721772
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-18
- Primary completion
- 2014-06-24
- Enrollment
- 418
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.